Methamphetamine and Other Substance Use During Pregnancy: Preliminary Estimates From the Infant Development, Environment, and Lifestyle (IDEAL) Study

  • Amelia M. Arria
  • Chris Derauf
  • Linda L. LaGasse
  • Penny Grant
  • Rizwan Shah
  • Lynne Smith
  • William Haning
  • Marilyn Huestis
  • Arthur Strauss
  • Sheri Della Grotta
  • Jing Liu
  • Barry Lester
Original Article

Objectives: Methamphetamine use is a continuing problem in several regions of the United States and yet few studies have focused on prenatal methamphetamine exposure. The purpose of this study was to estimate the prevalence and correlates of alcohol, tobacco, and other substance use—including methamphetamine—during pregnancy. Methods: The sample consisted of the first 1632 eligible mothers who consented to participate in a large-scale multisite study focused on prenatal methamphetamine exposure. This unselected screening sample included both users and nonusers of alcohol, tobacco, methamphetamine, and other drugs. Substance use was determined by maternal self-report and/or GC/MS confirmation of a positive meconium screen. Results: Overall, 5.2% of women used methamphetamine at some point during their pregnancy. One quarter of the sample smoked tobacco, 22.8% drank alcohol, 6.0% used marijuana, and 1.3% used barbiturates prenatally. Less than 1% of the sample used heroin, benzodiazapenes, and hallucinogens. Multivariate modeling results showed that tobacco smokers and illicit drug users were more likely to be single and less educated, have attended less than 11 prenatal visits, and utilize public financial assistance. Conclusions: This is the first large-scale investigation to report the prevalence of methamphetamine use during pregnancy in areas of the United States where methamphetamine is a notable concern. Follow-up research is ongoing to investigate the outcomes associated with prenatal methamphetamine exposure. Given that this research extends and confirms previous findings showing that high-risk groups of pregnant women can be identified on the basis of basic demographic characteristics, targeted interventions are greatly needed to reduce serious adverse outcomes associated with prenatal alcohol and tobacco use.


methamphetamine pregnancy alcohol and other drug use prenatal care epidemiology 


  1. 1.
    Lester BM, Andreozzi L, Appiah L. Substance use during pregnancy: Time for policy to catch up with research. Harm Reduction J 2004;1(5):1–44.CrossRefGoogle Scholar
  2. 2.
    Hanson JW, Jones KL, Smith DW. Fetal alcohol syndrome. Experience with 41 patients. JAMA 1976;235(14):1458–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Bauer CR. Perinatal effects of prenatal drug exposure: Neonatal aspects. Clin Perinatol 1999;26:87–106.PubMedGoogle Scholar
  4. 4.
    Streissguth AP, Barr HM, Martin DC, Herman CS. Effects of maternal alcohol nicotine, and caffeine use during pregnancy on infant mental and motor development at eight months. Alc Clin Exp Res 1980;4(2):152–64.CrossRefGoogle Scholar
  5. 5.
    Kramer MS. The etiology and prevention of low birthweight: Current knowledge and priorities for future research. In: Berendes H, Kessel S Yaffe S, (Eds.) Advances in the prevention of low birthweight. An international symposium. Washington, DC: National Center for Education in Maternal and Child Health, 1991.Google Scholar
  6. 6.
    Lassen K, Oei TPS. Effects of maternal cigarette smoking during pregnancy on long-term physical and cognitive parameters of child development. Addict Behav 23:635–53.Google Scholar
  7. 7.
    Law KL, Stroud LR, LaGasse LL, Niaura R. Smoking during pregnancy and newborn neurobehavior. Pediatrics 2003;111(6):1318–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Kandall SR, Albin S, Gartner LM, Lee KS, Eldelman A, Lowinson J. The narcotic-dependent mother: Fetal and neonatal consequences. Early Hum Dev 1977;1(2):159–69.CrossRefPubMedGoogle Scholar
  9. 9.
    Finnegan LP, Kaltenbach KA. Neonatal abstinence syndrome. In: Hoekelman RA, Nelson NM, Seidel HM, (Eds.) Primary Pediatric Care, 2nd Ed. St. Louis: Mosby, 1992: 1367–78.Google Scholar
  10. 10.
    Rangel C. The crack cocaine crisis (Joint hearings of Select Committee on Narcotics Abuse and control and select committee on children youth and families). Washington, DC, U.S. House of Representatives, 1986.Google Scholar
  11. 11.
    Lester BM, LaGasse LL, Seifer R. Cocaine exposure and children: The meaning of subtle effects. Science 1998;282:633–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Delaney-Black V, Covington C, Templin T, Ager J. Prenatal cocaine exposure and child behavior. Pediatrics 1998;102:945–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Leech S, Richardson GA, Goldschmidt L, Day NL. Prenatal substance exposure: Effects on attention and impulsivity of 6-year olds. Neurotoxicol Teratol 1999;21(2):109–18.CrossRefPubMedGoogle Scholar
  14. 14.
    Richardson GA, Conroy ML, Day NL. Prenatal cocaine exposure effects on the development of school-age children. Neurotoxicol Terat 1996;18(6):627–34.CrossRefGoogle Scholar
  15. 15.
    Messinger DS, Bauer CR, Abhik D, Seifer R, Lester BM, Lagasse LL, Wright LL, Shankaran S, Bada HS, Smergilio VL, Langer JC, Beeghly M, Poole WK. The maternal lifestyle study: cognitive motor and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 113:1677–85.Google Scholar
  16. 16.
    Lester BM. Vulnerable Infants Program of Rhode Island. Program funded by the Robert Wood Johnson Local Initiative Funding Partners Program and the Abandoned Infant Assistance Project, 2000.Google Scholar
  17. 17.
    Smeriglio VL, Wilcox HC. Prenatal drug exposure and child outcome: Past, present, future. In: Lester BM, (Eds.) Clinics in perinatology: Prenatal drug exposure and child outcome. Philadelphia, PA: WB Saunders, 1999:1–16.Google Scholar
  18. 18.
    Lukas SE. Proceedings of the National Consensus Meeting on the use, abuse, and sequelae of methamphetamine with implications for prevention, treatment, and research. Washington, DC: Center for Substance Abuse Treatment, 1997.Google Scholar
  19. 19.
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, National Survey on Drug Use and Health, 2002 and 2003.Google Scholar
  20. 20.
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Summary of findings from the 1999 National Household Survey on Drug Abuse (DHHS Publiciation No SMA00-3466, NHSDA Series H12, Rockville, MD.Google Scholar
  21. 21.
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, National Survey on Drug Use and Health, 2002 and 2003.Google Scholar
  22. 22.
    U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, DASIS Report: Primary Methamphetamine/Amphetamine Treatment Admissions 1992–2002, September 17, 2004.Google Scholar
  23. 23.
    Miller MA. History and epidemiology of amphetamine abuse in the United States. In: Klee H, (Ed.) Amphetamine misuse: International perspectives on current trends. Amsterdam: Harwood Academic, 1997:113.Google Scholar
  24. 24.
    Zhang Z. Drug and Alcohol Use and Related Matters among Arrestees. ADAM Program 2003, National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.Google Scholar
  25. 25.
    Acuff-Smith KD, George M, Lorens SA, Vorhees CV. Preliminary evidence for methamphetamine-induced behavioral and ocular effects in rat offspring following exposure during early organogenesis. Psychopharmacology 1992;109(3):255–63.CrossRefPubMedGoogle Scholar
  26. 26.
    Yamamoto Y, Yamanoto K, Fukui Y, Kurishita A. Teratogenic effects of methamphetamine in mice. Jpn J Legal Med 1992;46(2):126– 31.Google Scholar
  27. 27.
    Cho DH, Lyu HM, Lee HB, Kim PY, Chin K. Behavioral teratogenicity of methamphetamine. J Toxicol Sci Suppl 1991;1:37–49.Google Scholar
  28. 28.
    Cabrera TM, Levy AD, Li Q, van de Kar LD, Battaglia G. Prenatal methamphetamine attenuates serotonin mediated renin secretion in male and female rat progeny: Evidence for selective long-term dysfunction of serotonin pathways in brain. Synapse 1993;15(3):198–08.CrossRefPubMedGoogle Scholar
  29. 29.
    Weissman AD, Caldecott-Hazard S. Developmental neurotoxicity to methamphetamines. Clin Exp Pharmacol Physiol 1995;22(5):372–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Eriksson M, Larsson G, Winbladh B, Zetterstrom R. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand 1978;67:95–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Eriksson M, Larsson G, Zetterstrom R. Amphetamine addiction and pregnancy. II. Pregnancy, delivery, and the neonatal period. Socio-medical aspects. Acta Obstet Gynecol Scand 1981;60:253–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J Pediatr 1989;115:770–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates. J Pediatr 1987;111:571–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Little BB, Snell LM, Gilstrap LC. Methamphetamine abuse during pregnancy: Outcome and fetal effects. Obstet Gynecol 1988;72:541–4.PubMedGoogle Scholar
  35. 35.
    Struthers JM, Hansen RL. Visual recognition memory in drug-exposed infants. J Dev Behav Pediatr 1992;13:108–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Billing L, Eriksson M, Larsson G, Zetterstrom R. Amphetamine addiction and pregnancy. III. One year follow-up of the children. Psychosocial and pediatric aspects. Acta Paediatr Scand 1980;69:675–80.PubMedCrossRefGoogle Scholar
  37. 37.
    Billing L, Eriksson M, Steneroth G, Zetterstrom R. Pre-school children of amphetamine-addicted mothers. I. Somatic and psychomotor development. Acta Paediatr Scand 1985;74:179–84.PubMedCrossRefGoogle Scholar
  38. 38.
    Billing L, Eriksson M, Steneroth G, Zetterstrom R. Predictive indicators for adjustment in 4-year-old children whose mothers used amphetamine during pregnancy. Child Abus Negl 1988;12:503–7.CrossRefGoogle Scholar
  39. 39.
    Billing L, Eriksson M, Jonsson B, Steneroth G. The influence of environmental factors on behavioral problems in 8-year-old children exposed to amphetamine during fetal life. Child Abus Negl 1994;18:3–9.CrossRefGoogle Scholar
  40. 40.
    Cernerud L, Eriksson M, Jonsson B, Steneroth G, Zetterstrom R. Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatr 1996;85:204–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Catanzarite VA, Stein DA. ‘Crystal’ and pregnancy—Methamphetamine-associated maternal deaths. West J Med 1995;162:454–8.PubMedGoogle Scholar
  42. 42.
    Plessinger MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998;25(1):119–38.CrossRefPubMedGoogle Scholar
  43. 43.
    U.S. Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse. National Pregnancy and Health Survey: Drug Use among Women Delivering Live Births: 1992. NIH Publication No. 96–3819, 1996.Google Scholar
  44. 44.
    Derauf C, Katz AR, Frank DA, Grandinetti A, Easa D. The prevalence of methamphetamine and other drug use during pregnancy in Hawaii. J Drug Issues 2003;2–16.Google Scholar
  45. 45.
    U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Smoking during pregnancy—United States, 1990–2002. MMWR 2004;53:911–17.Google Scholar
  46. 46.
    U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Surveillance Summaries, Surveillance for disparities in maternal health-related behaviors—selected states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000-2001. MMWR 2004 53 SS4 1–14.Google Scholar
  47. 47.
    Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 2003;101(2):374–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Leonardson GR, Loudenberg R. Risk factors for alcohol use during pregnancy in a multistate study. Neroutoxicol Teratol 2003;25(6):651–8.CrossRefGoogle Scholar
  49. 49.
    Fuani EF, White J, Lee MJ, Allen M, Kuczynski E. Compliance with prenatal care visits in substance abusers. J Mat Fetal Neonatal Med 2003;14(5):329–32.CrossRefGoogle Scholar
  50. 50.
    Bauer CR, Shankaran S, Bada HS, Lester B, Wright LL, Krause-Steinrauf H, Smeriglio VL, Finnegan LP, Maza PL, Verter J. The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol 2002;186(3):487–95.CrossRefPubMedGoogle Scholar
  51. 51.
    Lester BM, Tronick EZ, LaGasse L, Seifer R, Bauer CR, Shankaran S, Bada HS, Wright LL, Smeriglio VL, Lu J, Finnegan LP, Maza PL. The maternal lifestyle study: Effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics 2002;110(6):1182–92.CrossRefPubMedGoogle Scholar
  52. 52.
    Hollingshead AB. Four factor index of social status. Department of Sociology: Yale University, New Haven, CT, 1975.Google Scholar
  53. 53.
    El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylanck L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol 2003;23(5):354–60.CrossRefPubMedGoogle Scholar
  54. 54.
    Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Rieber C, Vandersloot D, Zweben J, and the Methamphetamine Treatment Project Corporate Authors. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004;99:708–17.CrossRefPubMedGoogle Scholar
  55. 55.
    Finkelstein N. Treatment programming for alcohol and drug-dependent pregnant women. Special Issue: Maternal Drug Use: Issues and Implications for Mother and Child. Inter J Addict 1993;28(13):1275–309.Google Scholar
  56. 56.
    Svikis DS, Haug N, Lee J, Timpson R. Predictors of treatment participation and retention in an intensive outpatient program for pregnant drug abusing women. In: Harris LS, (Ed.), National Institute of Drug Abuse Research Monograph Series 163. Rockville, MD: National Institute on Drug Abuse, 1996:351.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Amelia M. Arria
    • 1
    • 11
  • Chris Derauf
    • 2
  • Linda L. LaGasse
    • 3
  • Penny Grant
    • 4
  • Rizwan Shah
    • 5
  • Lynne Smith
    • 6
  • William Haning
    • 7
  • Marilyn Huestis
    • 8
  • Arthur Strauss
    • 9
  • Sheri Della Grotta
    • 3
  • Jing Liu
    • 3
  • Barry Lester
    • 10
  1. 1.Center for Substance Abuse ResearchUniversity of MarylandCollege ParkUSA
  2. 2.Department of PediatricsUniversity of Hawaii, John A. Burns School of MedicineHonoluluUSA
  3. 3.Infant Development CenterWomen and Infants’ HospitalProvidenceUSA
  4. 4.University of Oklahoma College of MedicineTulsaUSA
  5. 5.Blank Children's HospitalDes MoinesUSA
  6. 6.Harbor-UCLA Medical CenterTorranceUSA
  7. 7.University of HawaiiJohn A. Burns School of MedicineHonoluluUSA
  8. 8.Clinical Pharmacology and Therapeutics BranchIntramural Research Program, National Institute on Drug AbuseBaltimoreUSA
  9. 9.Long Beach Memorial Medical CenterLong BeachUSA
  10. 10.Infant Development CenterWomen and Infants’ Hospital, and Brown Medical SchoolProvidenceUSA
  11. 11.Center for Substance Abuse ResearchUniversity of MarylandCollege ParkUSA

Personalised recommendations